Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Lecture12-drug-occupancy-studies
Document related concepts
Transcript
Goal: design design perospirone 11C-FLB457 perospirone 11C-FLB457 perospirone 11C-FLB457 perospirone perospirone perospirone Why? 11C-FLB457 11C-FLB457 11C-FLB457 From Vernaleken et al… In the Arakawa paper, where does the baseline (aka ‘control’) data come from? From Vernaleken et al… DOES THIS MAKE SENSE? Design of healthy control study: This is a “single dose” study – why? As opposed to _______________? Design of healthy control study: 11C-raclopride Baseline perospirone 11C-raclopride 11C-raclopride This is a “single dose” study – why? As opposed to _______________? 11C-raclopride Healthy controls Why use 11C-raclopride here? Goal: design ‘short’ ‘long’ design ‘short’ Ziprasodone Ziprasodone Ziprasodone Ziprasodone Ziprasodone Ziprasodone ‘long’ 11C-fallypride 11C-fallypride 11C-fallypride 11C-fallypride 11C-fallypride 11C-fallypride Again, where do the baseline data come from in this design? Can they do that? Problems? Allows for different levels of occupancy for different regions. Multiple doses of drug, I guess Lower EC50 for putamen compared to other (extrastriatal) regions means lower receptor occupancy by the drug (ziprasodone) for a given plasma concentration. Suggests that there is a discrepancy between single dose measurements of occupancy and ‘steady state dosing’ But what else could it be? Perhaps: Chronic treatment with Zipras leads to upregulation of receptors and lower occup levels… 001 Healthy controls Why use 11C-raclopride here? Dosimetry? Repeated scans on same day? Displaceability in striatum? DIFFERENT STUDIES DONE AT DIFFERENT CENTERS Goal: But to do microdose study, the drug company would have to give the chemical formula to the university PET center… so they could label it.
